progesterone receptor positive
Showing 1 - 25 of >10,000
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin
Recruiting
- Carcinoma, Ovarian Epithelial
- Low Grade Serous Adenocarcinoma of Ovary
- Letrozole tablets
- carboplatin AUC 5 and paclitaxel 175 mg/m2
-
Brescia, BS, Italy
- +1 more
Oct 26, 2022
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Houston (Radiation Therapy, Therapeutic
Active, not recruiting
- Estrogen Receptor Positive
- +3 more
- Radiation Therapy
- Therapeutic Conventional Surgery
-
Houston, TexasM D Anderson Cancer Center
Jun 14, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Breast Cancer Trial in Washington, Baltimore (Outcomes4Me, Semi-structured interview)
Recruiting
- Breast Cancer
- Outcomes4Me
- Semi-structured interview
-
Washington, District of Columbia
- +1 more
Jan 13, 2023
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer Trial in
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +9 more
- anastrozole
- +3 more
-
Boston, Massachusetts
- +1 more
Sep 9, 2022
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer Trial in
Terminated
- Estrogen Receptor-positive Breast Cancer
- +7 more
- everolimus
- +5 more
-
Atlanta, Georgia
- +2 more
Mar 10, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,
Active, not recruiting
- Estrogen Receptor Negative
- +6 more
- Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +8 more
Feb 3, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial
Withdrawn
- Anatomic Stage 0 Breast Cancer AJCC v8
- +28 more
- Carbon Dioxide Fractional Laser
- Questionnaire Administration
- (no location specified)
Jan 5, 2023
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8
Active, not recruiting
- Anatomic Stage II Breast Cancer AJCC v8
- +16 more
- Durvalumab
- Tremelimumab
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer Trial in
Recruiting
- Granulosa Cell Ovarian Cancer
- +2 more
- Onapristone ER
- Onapristone ER + Anastrozole
-
Basking Ridge, New Jersey
- +7 more
Aug 17, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,
Active, not recruiting
- Estrogen Receptor Negative
- +15 more
- Cyclophosphamide
- +6 more
-
Bellevue, Nebraska
- +3 more
Nov 30, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Anastrozole,
Active, not recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +6 more
- Anastrozole
- +6 more
-
Atlanta, Georgia
- +9 more
Oct 12, 2022
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial
Recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +20 more
- Focus Group
- +3 more
-
Sewell, New Jersey
- +6 more
Sep 14, 2022
HER2-positive Breast Cancer, HER2 Low, SYD-985 Trial in Aurora (Vic-trastuzumab duocarmazine (SYD985) + paclitaxel)
Recruiting
- HER2-positive Breast Cancer
- +26 more
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
-
Aurora, ColoradoUniversity of Colorado Cancer Center
Oct 22, 2021
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)
Active, not recruiting
- Androgen Receptor Positive
- +5 more
- Enobosarm
- +2 more
-
Corona, California
- +6 more
Jun 8, 2022
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma Trial in United States (Accelerated
Active, not recruiting
- Ductal Breast Carcinoma In Situ
- +6 more
- Accelerated Partial Breast Irradiation
- +2 more
-
Gilbert, Arizona
- +9 more
Jul 20, 2022
HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive Trial in United States (procedure, drug,
Active, not recruiting
- HER2/Neu Negative
- +3 more
- Computed Tomography
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 27, 2023
Breast Cancer Trial in United States (bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications Trial in Los Angeles (mucoadhesive
Completed
- Estrogen Receptor-positive Breast Cancer
- +7 more
- mucoadhesive oral wound rinse
- laboratory biomarker analysis
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Sep 17, 2020
Estrogen Receptor Positive, Obesity, Progesterone Receptor Positive Trial in Los Angeles (dietary supplement, behavioral, other)
Withdrawn
- Estrogen Receptor Positive
- +5 more
- Dietary Intervention
- +3 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Dec 15, 2020
Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum Trial in Philadelphia (PD-0332991)
Completed
- Adult Solid Tumor
- +38 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of The University of Pennsylvania
Feb 18, 2021